Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.58 | N/A | +5.54% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.58 | N/A | +5.54% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about their clinical developments. They are focused on navigating current market conditions.
Management highlighted ongoing progress in clinical trials.
They emphasized commitment to advancing their pipeline despite challenges.
Kodiak Sciences Inc reported a narrower loss than expected, which contributed to a positive stock reaction, with shares rising 1.27%. The company did not disclose revenue figures or future guidance, but management's comments suggest they are making progress in their clinical trials. Investors may view the EPS beat as a sign of better-than-anticipated operational performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IES HLDGS INC
Aug 7, 2020